Harmony Biosciences Holdings, Inc. $HRMY Shares Purchased by Nomura Holdings Inc.

Key Points

• Nomura Holdings Inc. increased its stake in Harmony Biosciences by 66.7%, acquiring an additional 35,075 shares, bringing their total ownership to approximately 87,682 shares valued at $2.91 million.
• Harmony Biosciences reported earnings of $0.68 per share for the last quarter, missing analysts' expectations of $0.78, although their revenue grew year-over-year by 16% to $200.49 million.
• The stock currently holds an average rating of "Buy" from analysts, with a target price of $51.00, amidst recent upgrades and downgrades from various equity research firms.

Nomura Holdings Inc. boosted its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 66.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 87,682 shares of the company's stock after purchasing an additional 35,075 shares during the quarter. Nomura Holdings Inc. owned about 0.15% of Harmony Biosciences worth $2,910,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Financial Management Professionals Inc. purchased a new position in Harmony Biosciences during the 1st quarter worth $29,000. Brooklyn Investment Group raised its position in Harmony Biosciences by 1,031.9% during the 1st quarter. Brooklyn Investment Group now owns 1,064 shares of the company's stock worth $35,000 after buying an additional 970 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in Harmony Biosciences during the 4th quarter worth $41,000. Caitong International Asset Management Co. Ltd purchased a new position in Harmony Biosciences during the 1st quarter worth $57,000. Finally, CWM LLC raised its position in Harmony Biosciences by 34.8% during the 1st quarter. CWM LLC now owns 2,704 shares of the company's stock worth $90,000 after buying an additional 698 shares during the last quarter. Hedge funds and other institutional investors own 86.23% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Deutsche Bank Aktiengesellschaft restated a "buy" rating and set a $55.00 price objective (up previously from $54.00) on shares of Harmony Biosciences in a research report on Thursday, July 10th. The Goldman Sachs Group assumed coverage on shares of Harmony Biosciences in a research report on Thursday, July 10th. They set a "neutral" rating and a $33.00 price objective for the company. Cantor Fitzgerald upgraded shares of Harmony Biosciences to a "strong-buy" rating in a research report on Tuesday, May 13th. Oppenheimer began coverage on shares of Harmony Biosciences in a research report on Monday, June 2nd. They set an "outperform" rating and a $61.00 price objective for the company. Finally, Mizuho upped their price target on shares of Harmony Biosciences from $44.00 to $48.00 and gave the stock an "outperform" rating in a research note on Thursday, May 15th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $51.00.

Harmony Biosciences Price Performance

Shares of NASDAQ:HRMY traded down $0.31 on Friday, reaching $35.99. 742,372 shares of the company were exchanged, compared to its average volume of 494,329. The company has a current ratio of 3.84, a quick ratio of 3.80 and a debt-to-equity ratio of 0.20. Harmony Biosciences Holdings, Inc. has a 1-year low of $26.47 and a 1-year high of $41.61. The firm has a market cap of $2.07 billion, a price-to-earnings ratio of 11.61, a price-to-earnings-growth ratio of 0.42 and a beta of 0.84. The company has a 50-day moving average of $35.47 and a 200-day moving average of $33.60.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.68 earnings per share for the quarter, missing analysts' consensus estimates of $0.78 by ($0.10). The company had revenue of $200.49 million for the quarter, compared to analyst estimates of $204.37 million. Harmony Biosciences had a return on equity of 26.34% and a net margin of 23.44%.The business's revenue for the quarter was up 16.0% compared to the same quarter last year. During the same period last year, the company earned $1.05 earnings per share. Harmony Biosciences has set its FY 2025 guidance at EPS. Equities analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.